IL17A and neoplasm: In addition to BCL2A1 expression, we also identified a pre-M2 phenotype in IL-17A-treated DC, opening the view that, in the absence of IFN-γ, IL-17A-dependent myeloid cell plasticity may give rise to M2-like tumor-associated macrophages [30].